Skip to main content
Search
About Us
Investor Relations
Media
Products
Careers
Contact Us
Press Releases
2010
2009
2008
2007
2006
2005
2004
2003
Archive
Press Kit
Media Contacts
Print Page
You are here \
Home
\
Media
\
Press Releases
\
Archive
Press Releases
Register for email alerts
2010
2009
2008
2007
2006
2005
2004
2003
Archive
Date
Title
20 Dec 2002
In-Licensed Embolic Microsphere Receives US FDA Clearance
11 Nov 2002
Board Appointment
05 Nov 2002
Isostent Claim - Update
26 Sep 2002
Outcome of Strategic Review
26 Sep 2002
Interim Results for Six Months Ended 30 June 2002
25 Jul 2002
Listing of New Ordinary Shares
25 Jul 2002
High Court Confirms Reduction of Capital
04 Jul 2002
Result Of Extraordinary General Meeting
27 Jun 2002
New Development Programme for PC Gel Systems Initiated
11 Jun 2002
Posting of circular containing details of the proposed repayment of capital to shareholders
05 Jun 2002
Annual General Meeting Set for 27 June 2002
08 May 2002
Completion of the Sale of the Cardiovascular Stent Business
03 May 2002
Receipt of payment for Cooper Loan Note
23 Apr 2002
Result of Extraordinary General Meeting
05 Apr 2002
Return of Capital
18 Mar 2002
Preliminary results for the year ended 31 December 2001
18 Mar 2002
Biocompatibles Announces Positive Clinical Trial Results
18 Mar 2002
Biocompatibles Announces Sale of Cardiovascular Stent Business
08 Mar 2002
Biocompatibles Files for CE Mark Approval for Dextra Stent
08 Mar 2002
Suspension of patient recruitment in the BRILLIANT II Clinical Trial
04 Mar 2002
Pre-Market Approval of the Phosphorylcholine (PC)
14 Feb 2002
Result of Extraordinary General Meeting
08 Feb 2002
Biocompatibles Commences Randomized Trial of 17?-Estradiol Loaded Coronary Stents
23 Jan 2002
Update on the Status of the Batimastat BiodivYsio Stent IDE Application
15 Jan 2002
Sale of the Eye Care Division
03 Jan 2002
Update on Clinical Trial Programme for the Batimastat BiodivYsio Stent
03 Jan 2002
Pre-Market Approval of the BiodivYsio Small Vessel Over-The-Wire Coronary Stent
24 Oct 2001
Third Quarter Sales, Current Trading, Product Launches and Drug Delivery Programme Update
24 Oct 2001
Third Quarter Sales, Current Trading, Product Launches and Drug Delivery Programme Update
21 Aug 2001
Commencement of clinical trial programme for the Batimastat BiodivYsio? stent
21 Aug 2001
Start of Clinical Trial for Proclear Compatibles Contact Lenses in Japan
14 Aug 2001
Interim Results
16 Jul 2001
AGM Statement
06 Jul 2001
US launch and Licence Agreements
24 May 2001
Biocompatibles Update on New Product Developments
09 May 2001
Appointment of Finance Director
23 Mar 2001
Biocompatibles receives CE Mark Approval for its new BiodivYsio™ Small Vessel ("SV")
14 Mar 2001
Abbott Announces Pre-clinical Data on Drug Delivery Stent
09 Mar 2001
Preliminary Results for the Year Ended 31 December 2000
24 Jan 2001
Update on Stent Drug Delivery and Agreement with British Biotech and Abbott Laboratories
24 Jan 2001
Biocompatibles and British Biotech to Collaborate on Batimastat BiodivYsio Stent
01 Nov 2000
Companies Announcement Office
03 Oct 2000
Board Appointment
03 Oct 2000
PMA Approval for BiodivYsio Coronary Stent
12 Sep 2000
Approvable Notification Received from FDA for BiodivYsioTM Stent
12 Sep 2000
Interim Results for Six Months Ended 30 June 2000
06 Jul 2000
AGM Statement
22 May 2000
Positive Results of US Coronary Stent Clinical Trial and Update on US Product Approval Process
09 Mar 2000
Acquisition of Hydron Limited for 38 million and Placing to Raise 31 million
28 Feb 2000
BiodivYsio Stent Update
26 Nov 1999
BiodivYsio Drug Delivery Stent receives European Marketing Approval
22 Nov 1999
Agreement with Abbott Laboratories, Trading Update and Warrant Exercise Timetable
22 Nov 1999
Agreement with Abbott Laboratories for Vascular Products and PC Coating Technology
02 Nov 1999
Contact Lens Product Recall
26 Sep 1999
Placing and Open Offer
30 Jul 1999
Interim results for the six months ended 30 June 1999
04 Mar 1999
Preliminary Results for the 12 months ended 31 December 1998
26 Feb 1999
Preliminary Results
11 Jan 1999
This Document is Important and Requires Your Immediate Attention
Back to Top